Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare, acquired neurological disorder with heterogeneous presentation. It is a peripheral nerve system immune-mediated condition which ...

Premiering on National Geographic Channel, November 24 at 10/9c. Stream on Hulu November 29.

(BPT) – “At first I was kind of like, what is that? What is CIDP? I’ve never heard of that. But then, the relief set in more than confusion … because at least there was a name to what I had.” ...

This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

Argenx (ARGX) announced that Health Canada has issued a notice of compliance authorizing Vyvgart as a monotherapy for the treatment of adult ...

The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...

Patients who received Vyvgart Hytrulo experienced a longer time to clinical deterioration compared with those who received placebo. The Food and Drug Administration (FDA) has approved Vyvgart ® ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...